Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dejuania Brown-rawls (NPI 1730379132)

Field	Value
Entity Type	Individual
Organization	Dejuania Brown-rawls
Address	8121 Rourk St
City	Myrtle Beach
State	SC
ZIP	29572
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 31, 2007

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

Provider is effectively a single-payer Medicare practice: Total Medicare revenue is $2.8M and there is no Medicaid billing on file (none below). The NPI was enumerated 2007-07-31 (~19 years ago), indicating long-standing Medicare participation without observable Medicaid activity, which implies payer mix and contract strategy will be driven almost exclusively by Medicare economics.

Revenue concentration is high: the precomputed top‑3 Medicare codes account for 55.3% of this provider's total Medicare revenue, with J9271 representing 35.4%, J0897 10.7%, and J1569 9.3%. This concentration shows a heavy dependence on a small set of injectable biologics and specialty products for the practice’s Medicare revenue.

The code mix points to an infusion‑centric hematology/oncology operation: the top revenue drivers are J9271 (pembrolizumab), J0897 (denosumab), and J1569 (immune globulin), and administration codes such as 96413 (chemotherapy administration) and 96365 (initial IV infusion) also appear in the top 25. Combined with frequent lab (85025, 36415) and PET/CT imaging (78815, A9552) codes, the pattern is consistent with an office‑based or clinic‑embedded infusion practice that delivers oncologic biologics, supportive bone/iron therapies, and routine diagnostic monitoring.

Competitive standing is mixed across products: J9271 (pembrolizumab) generates the single largest share of revenue at 35.4% but ranks #327 of 1841 nationally (82th percentile; typical, unremarkable volume), indicating a solid but not dominant national position for that high‑revenue drug. By contrast, J0897 (denosumab) ranks #506 of 10057 (95th percentile; notably above typical national volume) and J1437 (ferric derisomaltose) ranks #14 of 581 (98th percentile; notably above typical), signaling above‑typical local/regional intensity for bone‑support and IV iron interventions.

Visit and complexity metrics show unusually high E/M coding: 99214 (established patient, moderate complexity) is listed as an "extreme outlier" (ranks #1653 of 479517, 100th percentile) and 99205 (new patient, high complexity) is also an "extreme outlier" (98th percentile). These outlier E/M volumes suggest heavy visit throughput and a high proportion of complex evaluation visits, consistent with active oncology care and ongoing management of complex chronic conditions.

Ancillary diagnostics and lab throughput are substantial: PET/CT imaging (78815) contributes $146.2K and ranks in the 84th percentile nationally, A9552 (FDG dose) is in the 89th percentile, and routine lab codes such as 85025 and 36415 rank in the high percentiles (98th–99th). This combination supports an integrated model where imaging and frequent laboratory monitoring are routine components of care delivery and revenue generation.

Operationally, reliance on high‑cost biologics creates both revenue upside and concentration risk: with J9271 alone accounting for 35.4% of Medicare revenue and the top three codes totaling 55.3%, payers and contracting teams should note that changes in drug utilization, reimbursement, or site‑of‑care reimbursement could materially affect practice revenue. The prominence of supportive agents (J0897, J1437) and immune therapies (J9271, J9299) indicates supply chain and buy‑and‑bill management are likely core operational priorities.

The absence of Medicaid activity (none below) meaningfully narrows the provider’s covered population and payer exposure: this limits Medicaid patient access through this clinician and will affect network coverage analyses and any Medicaid‑focused competitive assessment, while concentrating financial and utilization analysis on Medicare claims trends and national benchmark percentiles.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

86 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,410	$40	$920.6K
J0897	Injection, denosumab, 1 mg	15,420	$20	$277.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,700	$40	$241.2K
J1437	Injection, ferric derisomaltose, 10 mg	12,500	$20	$200K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,880	$90	$173.1K
J9299	Injection, nivolumab, 1 mg	6,840	$20	$164.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	200	$720	$146.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$90	$59.7K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	9,640	$10	$57.8K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	230	$200	$45.9K

Showing 1–10 of 86

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 86 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Dejuania Brown-rawls — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

86 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	30	19,700	$40	$832K
J9299	14	10	15,760	$20	$432K
J1569	2	20	3,860	$40	$161.4K
J1437	2	10	6,240	$20	$107.6K
J0897	21	250	2,400	$20	$91.2K
J3490	9	50	70	$510	$57.7K
78815	18	120	80	$220	$25.8K
99214	50	7,860	160	$80	$23.2K
96413	8	150	140	$90	$22.1K
J0885	3	20	2,220	$10	$21.3K

Showing 1–10 of 86

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dejuania Brown-rawls, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jordan Henderson	SC	Hematology & Oncology Physician	$3.1M	$0
Patrick Francke	SC	Radiation Oncology Physician	$2.8M	$0
David Zaenger	SC	Radiation Oncology Physician	$2.3M	$0
Renwick Goldberg	SC	Hematology & Oncology Physician	$2.2M	$0
Stephen Andrews	SC	Radiation Oncology Physician	$2M	$0
Nikhil Patel	SC	Hematology & Oncology Physician	$1.9M	$0
Emily Touloukian	SC	Hematology & Oncology Physician	$1.5M	$0
Vijay Paudel	SC	Hematology & Oncology Physician	$912.8K	$0
Tanya Bralley	SC	Medical Physician Assistant	$208.3K	$0
Angela Brinegar	SC	Adult Health Nurse Practitioner	$152.6K	$0

Nearby Providers

Other providers in the same ZIP code as Dejuania Brown-rawls, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Acs Primary Care Physicians - Southeast PC	SC	Emergency Medicine Physician	$0	$81.7M
Grand Strand Pediatrics & Adolescent Medicine, P.A.	SC	Pediatric Adolescent Medicine Physician	$0	$28M
Grand Strand Regional Medical Center LLC	SC	General Acute Care Hospital	$0	$27.4M
Carolina Regional Surgery Center. Ltd	SC	Ambulatory Surgical Clinic/Center	$3M	$1.7M
Coastal Carolina Primary Care, LLC	SC	Endocrinology, Diabetes & Metabolism Physician	$0	$4M
Brandon Coakley	SC	MOHS-Micrographic Surgery Physician	$3.5M	$0
Parkway Surgery Center	SC	Ambulatory Surgical Clinic/Center	$3.5M	$0
David Lazar	SC	Rheumatology Physician	$2.7M	$0
Stephen Hammond	SC	Dermatopathology Physician	$2.3M	$0
David Chetrit	SC	Rheumatology Physician	$2.3M	$0

Dejuania Brown-rawls — Billing Profile & Reimbursement Data

Sign up for Dejuania Brown-rawls — Billing Profile & Reimbursement Data policy alerts

Dejuania Brown-rawls — Billing Profile & Reimbursement Data

Sign up for Dejuania Brown-rawls — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References